Human medicines European public assessment report (EPAR): Lacosamide Adroiq, lacosamide, Epilepsy, Date of authorisation: 31/05/2023, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Plenadren, hydrocortisone, Adrenal Insufficiency, Date of authorisation: 03/11/2011, Revision: 14, Status: Authorised
Guideline on the calculation of dose factor to be submitted to the Union Product Database (UPD)
Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Neuromuscular Blockade, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): levonorgestrel, decision type: , therapeutic area: , PIP number: P/0447/2022
Opinion/decision on a Paediatric investigation plan (PIP): Efanesoctocog alfa, decision type: , therapeutic area: , PIP number: P/0382/2022
Opinion/decision on a Paediatric investigation plan (PIP): ritlecitinib, decision type: , therapeutic area: , PIP number: P/0446/2022
Opinion/decision on a Paediatric investigation plan (PIP): Gepotidacin, decision type: , therapeutic area: , PIP number: P/0444/2022
Membership list - HMA / EMA joint Big Data Steering Group
Opinion/decision on a Paediatric investigation plan (PIP): Fluorine (18F) PSMA-1007, decision type: , therapeutic area: , PIP number: P/0430/2022